View Older Stories View More Recent Stories

Aug 14, 2018 04:49PM VistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results
Aug 14, 2018 04:49PM VistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results
Aug 13, 2018 08:35AM VistaGen Therapeutics (VTGN) Announces Collaboration with Baylor College of Medicine on First-Step Study to Evaluate AV-101 for Potential Anti-Suicidal Effects in Veterans
Aug 13, 2018 08:30AM VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen’s AV-101 for Potential Anti-Suicidal Effects in Veterans
Aug 13, 2018 08:30AM VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen’s AV-101 for Potential Anti-Suicidal Effects in Veterans
Jun 26, 2018 05:12PM VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights
Jun 26, 2018 05:12PM VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights
Jun 13, 2018 08:34AM VistaGen Therapeutics (VTGN) Granted Two U.S. Patents for Treatment of Depression with AV-101
Jun 13, 2018 08:30AM VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101
Jun 13, 2018 08:30AM VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101
Jun 11, 2018 08:31AM VistaGen Therapeutics (VTGN) Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders
Jun 11, 2018 08:30AM VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders
Jun 11, 2018 08:30AM VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders
May 23, 2018 08:32AM VistaGen Therapeutics (VTGN) Granted U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage
May 23, 2018 08:30AM VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage
May 23, 2018 08:30AM VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage
May 2, 2018 08:31AM VistaGen Therapeutics (VTGN) Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101
May 2, 2018 08:30AM VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101
May 2, 2018 08:30AM VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101
Apr 10, 2018 08:32AM VistaGen Therapeutics (VTGN) Receives European Patent regarding Methods of Production for AV-101
Apr 10, 2018 08:30AM VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101
Apr 5, 2018 08:03AM VistaGen Therapeutics (VTGN) Commences Phase 2 Study of AV-101 for Major Depressive Disorder
Apr 5, 2018 08:00AM VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder
Mar 19, 2018 10:20AM VistaGen Therapeutics (VTGN) Reports Notice of Allowance for U.S. Patent Covering Oral Formulations of AV-101
Mar 19, 2018 10:17AM VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101
Mar 7, 2018 09:02AM VistaGen Therapeutics (VTGN) Receives Notice of Allowance for Key U.S. Patent Covering Treatment of Depression with AV-101
Mar 7, 2018 09:00AM VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101
Mar 5, 2018 09:02AM VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018
Feb 27, 2018 08:30AM VistaGen Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018
Feb 12, 2018 04:30PM VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results
Jan 22, 2018 08:30AM VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference
Jan 3, 2018 08:31AM VistaGen Therapeutics (VTGN) Receives FDA Fast Track Designation for AV-101 for the Treatment of MDD
Jan 3, 2018 08:30AM VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder
Dec 18, 2017 08:30AM VistaGen Therapeutics to Present at the 10th Annual Biotech Showcase
Dec 13, 2017 04:30PM VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
Dec 11, 2017 09:28AM VistaGen Therapeutics (VTGN) Prices 10M Offering of Common Stock and Warrants
Dec 11, 2017 09:25AM VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
Dec 8, 2017 09:02AM VistaGen Therapeutics (VTGN) Grated Patent Related to Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer
Dec 8, 2017 09:00AM VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders an
Dec 6, 2017 09:18AM VistaGen Therapeutics (VTGN) Secures U.S. Patent on Methods of Production for AV-101
Dec 6, 2017 09:08AM VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101
Nov 9, 2017 04:30PM VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update
Nov 6, 2017 08:36AM VistaGen Therapeutics (VTGN) Granted European Patent for AV-101 for Treatment of Depression
Nov 6, 2017 08:30AM VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression
Oct 26, 2017 07:41AM VistaGen Therapeutics (VTGN) Reports FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder
Oct 26, 2017 07:30AM VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder
Sep 28, 2017 08:06AM VistaGen Therapeutics (VTGN) Receives Notice of Allowance for U.S. Patent Regarding Methods of Production for AV-101
Sep 28, 2017 08:00AM VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101
Sep 6, 2017 04:15PM VistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
Aug 31, 2017 09:28AM VistaGen Therapeutics (VTGN) Prices $2.4M Offering of Common Stock and Warrants
View More Recent Stories View Older Stories